Experimental drug shows promise for Hard-to-Treat lymphoma
NCT ID NCT02588651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of that marker are very low. The main goal was to see how many patients' tumors shrank or disappeared after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
-
Wayne State University, Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can a targeted antibody boost chemotherapy against a rare leukemia?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma
- New study aims to decode PTCL by genetic subtype
- Promising combo tackles rare blood cancer in chinese patients